MKKGY vs TAK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MKKGY · MERCK KGAA SPON ADR EACH REPR 0.2 ORD SHS$33.17 ▼ 0.66%
TAK · Takeda Pharmaceutical$21.02 ▼ 0.80%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MKKGY +32.7%
- TAK +55.9%
Head to head
| Metric | MKKGY | TAK |
|---|---|---|
| Price | $33.17 | $21.02 |
| Change today | ▼ 0.66% | ▼ 0.80% |
| Market cap | $67.11B | $67.36B |
| Return, 3 months | -0.1% | +19.8% |
| Return, year to date | +18.0% | +37.1% |
| Return, 1 year | +33.3% | +56.5% |
| P/E (TTM) | 26.1 | 296.1 |
| P/B | 2.1 | 1.4 |
| P/E percentile vs own 5y | – | 100th |
| Dividend yield | 1.55% | 1.49% |
| Revenue growth (YoY, latest qtr) | – | +6.7% |
| Net profit growth (YoY) | – | +1,740.9% |
| Gross margin | – | 65.8% |
| Operating margin | – | 14.3% |
| Net margin | – | 0.9% |
| Return on equity | – | 0.6% |
| Analyst target vs. price | – | +104.1% |
| Analyst buy share | – | 100% |
| RSI (14) | 56 | 69 |
| 30-day volatility | 27.9% | 23.6% |
| Max drawdown, 1 year | -22.9% | -19.9% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- TAK is the largest of the group by market value.
- TAK has returned the most over the past year.
- MKKGY carries the lowest trailing P/E.
- MKKGY pays the highest dividend yield.
- TAK has been the calmest stock over the last 30 days.